Condition: Advanced Solid Tumors With Homozygous MTAP Deletion · Sponsor: Bristol-Myers Squibb
The purpose of this study is to evaluate the mass balance, metabolism, elimination, and drug levels of \[14C\]-BMS-986504 (MRTX1719) in participants with advanced solid tumors with homozygous methylthioadenosine phosphorylase deletion.
This description comes directly from the study's public registry record.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Always discuss trial participation with your own doctor first.
| ICON / PRA Magyarország Kft. Fázis I-es Klinikai Farmakológiai Vizsgálóhely | Budapest, Hungary | Recruiting |
| START Rioja, The START Center for cancer research | Logroño, Spain | Recruiting |
| Centro Integral Oncologico Clara Campal-Hospital HM Universitario Sanchinarro-START Madrid, | Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06672523